<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669223</url>
  </required_header>
  <id_info>
    <org_study_id>UW 20-582</org_study_id>
    <nct_id>NCT04669223</nct_id>
  </id_info>
  <brief_title>Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion</brief_title>
  <official_title>Clinical Efficacy and Complications of Small-bore Versus Ultra-small Bore Chest Drain in Malignant Pleural Effusion: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural effusion (MPE) is a very common medical condition, especially among&#xD;
      patients with disseminated cancers. Chest drain insertion aims to drain the pleural fluid&#xD;
      collection and relieve dyspnea. Small bore chest tubes are recommended as the first line&#xD;
      therapy for draining pleural effusions. However, there is no clinical data available to&#xD;
      inform on the size of drains for better drainage. This is a randomized study comparing the&#xD;
      two common bores of small bore chest drains in Hong Kong, and assess for its clinical&#xD;
      efficacy and complication risks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Malignant pleural effusion (MPE) is the commonest complication of lung cancer,&#xD;
      and its associated symptoms are frequent causes of hospitalizations and morbidities in&#xD;
      patients with disseminated cancers. Chest tube drainage is often performed for symptomatic&#xD;
      relief. Recent clinical trials had shown that large-bore chest drains (&gt;14 French) caused&#xD;
      significantly more pain than smaller drain during the insertion procedure and when the drain&#xD;
      was in situ, which prompts the shift of preference towards smaller chest drains in guideline&#xD;
      and clinical practice. Chest drains as small-bore as 7-8 French have been used in many local&#xD;
      centers for drainage of MPE, though little attention has been made to the possible higher&#xD;
      occurrence of drain blockage, kinking or dislodgement before optimal effusion drainage is&#xD;
      achieved, which may lead to a second procedure for drain replacement. Currently, there is no&#xD;
      data informing the efficacy and complications of ultra-small chest drains in clinical use.&#xD;
      Therefore, it is imperative to call for further research on the optimal size of the chest&#xD;
      drain which can achieve satisfactory drainage and at the same time, of minimal complications.&#xD;
&#xD;
      Study design: Single-center, parallel group, single blinded, randomized controlled study&#xD;
      Study site: Department of Medicine, Queen Mary Hospital Target study participants: Subjects&#xD;
      with symptomatic MPE requiring chest drainage&#xD;
&#xD;
      Method and analysis: This randomized controlled study to compare the efficacy of ultra-small&#xD;
      bore chest drains (8 Fr) with standard small bore chest drain (14 French) as the reference.&#xD;
      Primary outcome is drain success defined by nearly complete drainage of MPE on chest&#xD;
      radiograph on day 5 of the drain. Other secondary outcomes include pain according to the&#xD;
      visual analogue scale, dyspnea relief and complications during the procedure and post - chest&#xD;
      drain insertion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with drainage success by day 5 of chest drain</measure>
    <time_frame>Day 5 of chest drain insertion</time_frame>
    <description>Drain success is defined by achieving nearly complete drainage through chest-x ray or ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessed by visual analogue scale ( score from 1 to 10 )when drain is in-situ</measure>
    <time_frame>Day 5 of chest drain insertion</time_frame>
    <description>To record pain through visual analogue scale, which in higher score signifies worse pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnea assessed by visual analogue scale for dyspnea ( score from 1 to 10 )</measure>
    <time_frame>Day 5 of chest drain insertion</time_frame>
    <description>To record change in dyspnea through the dyspnea visual analogue scale, which a higher score signifies worse dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications during and after insertion</measure>
    <time_frame>Day 5 of chest drain insertion</time_frame>
    <description>To record and analyse complications during and after insertion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Pleural Effusion, Malignant</condition>
  <condition>Lung Cancer Stage IV</condition>
  <condition>Chest Tubes</condition>
  <arm_group>
    <arm_group_label>Seldinger chest drain 14F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with seldinger chest drain 14F inserted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seldinger chest drain 8F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with seldinger chest drain 8F inserted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seldinger chest drain insertion</intervention_name>
    <description>Different sizes of chest drain will be inserted with seldinger technique</description>
    <arm_group_label>Seldinger chest drain 14F</arm_group_label>
    <arm_group_label>Seldinger chest drain 8F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have cytologically/histologically proven pleural malignancy, or who have&#xD;
             pleural effusion in the context of malignancy elsewhere&#xD;
&#xD;
          -  The pleural effusion is at least moderate to massive and causes symptoms&#xD;
&#xD;
          -  Ability to give informed written consent to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  Bleeding tendency not readily correctable (platelet &lt; 100 x 10^9, INR â‰¥1.5 after&#xD;
             transfusion)&#xD;
&#xD;
          -  Hydropneumothorax before drain insertion&#xD;
&#xD;
          -  Moderate-heavy septations in the pleural effusion (defined as a collection with more&#xD;
             than 4 septations visible at the maximally septated area)&#xD;
&#xD;
          -  Clinical emergency that an urgent chest drain is required&#xD;
&#xD;
          -  Allergy to local anesthesia agents&#xD;
&#xD;
          -  Blindness&#xD;
&#xD;
          -  History of pleurodesis on the same side of malignant pleural effusion requiring&#xD;
             drainage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei Sze Macy Lui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ka Yan Chiang, MBBS(HK)</last_name>
    <phone>25182111</phone>
    <email>fifianchiang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei Sze Macy Lui, MD</last_name>
    <phone>25182111</phone>
    <email>drmslui@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ka Yan Chiang, MBBS(HK)</last_name>
      <phone>25182111</phone>
      <email>fifianchiang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Macy Mei Sze Lui, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Havelock T, Teoh R, Laws D, Gleeson F; BTS Pleural Disease Guideline Group. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii61-76. doi: 10.1136/thx.2010.137026.</citation>
    <PMID>20696688</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahman NM, Pepperell J, Rehal S, Saba T, Tang A, Ali N, West A, Hettiarachchi G, Mukherjee D, Samuel J, Bentley A, Dowson L, Miles J, Ryan CF, Yoneda KY, Chauhan A, Corcoran JP, Psallidas I, Wrightson JM, Hallifax R, Davies HE, Lee YC, Dobson M, Hedley EL, Seaton D, Russell N, Chapman M, McFadyen BM, Shaw RA, Davies RJ, Maskell NA, Nunn AJ, Miller RF. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA. 2015 Dec 22-29;314(24):2641-53. doi: 10.1001/jama.2015.16840. Erratum in: JAMA. 2016 Feb 16;315(7):707. JAMA. 2016 Apr 19;315(15):1661.</citation>
    <PMID>26720026</PMID>
  </results_reference>
  <results_reference>
    <citation>Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest. 2001 Jul;120(1):19-25.</citation>
    <PMID>11451810</PMID>
  </results_reference>
  <results_reference>
    <citation>Hallifax RJ, Psallidas I, Rahman NM. Chest Drain Size: the Debate Continues. Curr Pulmonol Rep. 2017;6(1):26-29. doi: 10.1007/s13665-017-0162-3. Epub 2017 Jan 26. Review.</citation>
    <PMID>28344925</PMID>
  </results_reference>
  <results_reference>
    <citation>Mishra EK, Corcoran JP, Hallifax RJ, Stradling J, Maskell NA, Rahman NM. Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions. PLoS One. 2015 Apr 15;10(4):e0123798. doi: 10.1371/journal.pone.0123798. eCollection 2015.</citation>
    <PMID>25874452</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Lui Mei Sze</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

